The ability to rapidly identify active compounds in a complex mixture (e.g., natural products extract) is still one of the major problems in natural products screening programs. An elegant way to overcome this problem is to separate the complex mixture by gradient liquid chromatography followed by online biochemical detection parallel with chemical characterization, referred to as high-resolution screening (HRS). To find and identify phosphodiesterase (PDE) inhibitors in natural products extracts using the HRS technology, the authors developed a continuous-flow PDE enzymatic assay. The suitability of the continuous-flow PDE enzymatic assay for natural products screening was demonstrated. After optimization of the continuousflow PDE assay, the limit of detection for 3-isobutyl-1-methyl-xanthine (IBMX) was 1 µM, with a dynamic range from 1 to 100 µM IBMX. The applicability of the HRS technology for the detection of PDE inhibitors in natural products extracts was demonstrated by the analysis of a plant extract spiked with 2 naturally occurring PDE inhibitors. The plant extract was analyzed with 2 assay lines in parallel, enabling background fluorescence correction of the sample. The simultaneous quantification of the active compounds using evaporative light-scattering detection allowed the estimation of the IC 50 value of the active compounds directly in the crude extract. (Journal of Biomolecular Screening 2003:421-429) 
INTRODUCTION
T he cyclic nucleotide phosphodiesterase (PDE) enzyme family catalyzes the hydrolysis of guanosine cyclic 3′,5′monophosphate (cGMP) and adenosine cyclic 3′,5′monophosphate (cAMP) to GMP and AMP, respectively. Different molecular forms of PDE are present in mammalian cells. These isozymes differ with respect to substrate specificity, intracellular location, sensitivity to inhibitors, and mode of regulation. 1 Finding selective inhibitors of the different PDE isozymes would be therapeutically useful in the treatment of diseases such as hypertension, heart failure, erectile dysfunction, and asthma. [2] [3] [4] Consequently, this family of enzymes has been studied extensively, and numerous assays have been used to monitor their activity. [5] [6] [7] The most widely used assays are radiometric and employ 32 P-, 14 C-, or 3 H-labeled purine nucleotide substrate. 8, 9 Traditionally, many PDE inhibitors originate from natural product sources, [10] [11] [12] and about one-third of all current drugs are from natural origin or derived from natural products. 13, 14 Pharmacologically active compounds have been isolated from a wide variety of natural sources, ranging from marine organisms 15 to microbes. 16 However, only a small fraction of all lower and higher organisms has been investigated for the presence of bioactive compounds. Moreover, nature provides an unmatched chemical diversity of compounds, especially compared to synthesized libraries. Hence, it is likely that nature will continue to provide us with potentially new drugs, given the fact that we exploit the natural sources for this purpose. The first step in natural prod-ucts screening is to determine whether an extract possesses the desired biological activity. A common approach is to perform a biological assay in batch. The next step is the identification of the active compound in the complex mixture responsible for the activity found in the natural products extract. An often-used strategy is to fractionate the complex mixture using centrifugal partition chromatography or preparative high-performance liquid chromatography (HPLC), drying the fractions to remove the HPLC solvents, resuspending the dried fraction in assay-compatible solvent, and subsequently resubmitting each individual fraction to the original batch assay. This process has to be repeated until the active compound is pure to unequivocally identify the compound as being active; subsequently, the compound can be characterized. In addition to the risk of losing the activity during the drying or resuspending cycles, this process is very time and labor intensive. Moreover, many resources are invested in the isolation of, what later appears to be, an already known or uninteresting compound. The process of determining whether the activity in a complex mixture was caused by an already known or uninteresting compound (or by a potentially new drug) is called dereplication and is one of the most resource-consuming steps in natural products screening. [17] [18] [19] An efficient dereplication process will prevent the waste of valuable resources on the isolation and identification of useless active compounds. The recent application of high-throughput screening (HTS) technologies to natural products screening has greatly increased the number of "hits" found in natural screening programs. For this reason, the need for efficient dereplication processes has become even more profound. A technique that would most efficiently allow doing so is the online coupling of HPLC with biochemical detection and parallel chemical analysis, referred to as high-resolution screening (HRS). 20 In HRS, a complex mixture is separated using reversed-phase liquid chromatography (LC). A postcolumn biochemical assay determines the activity of the individual compounds present in the complex mixture, whereas parallel mass spectrometry (MS) and diode-array detection (DAD) chemically characterize the active compound(s). The structural information, which is obtained from MS, is extremely useful for the chemical characterization of the active compounds in natural products extracts. In addition to the structural identity of the compounds, information on the concentration is also required. DAD is a concentration-sensitive detection technique but relies on the solutes being UV active and having similar extinction coefficients. However, quantification of unknown compounds cannot be obtained with UV detection. Quantification of unknown active compounds can be performed using evaporative light-scattering detection (ELSD) because the response of the ELSD solely depends on the amount of compound being detected. The use of ELSD requires only that the compound is not a volatile compound. 21, 22 Performing the quantification of active compound in a complex mixture simultaneously with the bioassay allows hit ranking according to potency.
Although the HRS technology employs an LC separation step prior to the assay, the throughput is limited to about 1 sample in 10 minutes. To allow the screening of large numbers of natural products extracts in a relatively short time, the LC separation step can be omitted for the primary screening. This primary screening, using the flow-injection continuous-flow biochemical assay, is referred to as FlowScreening. Subsequently, the positive natural products extracts are reanalyzed using HRS, eliminating the false positives and generating both biological and chemical information on the active compound.
This article presents the development of a homogeneous continuous-flow enzymatic assay for PDE based on the fluorescence reduction of the fluorescent substrate, mant-guanosine 3′,5′cyclic monophosphate (mant-cGMP), upon hydrolysis. [23] [24] [25] The FlowScreening assay is validated for the primary screening of natural products by calculation of the Z′ and Z factor. 26 The applicability of the HRS technology is demonstrated by analysis of a natural products extract spiked with 2 naturally occurring PDE inhibitors. In parallel, bioactivity, native fluorescence, ELSD, DAD, and MS were measured in a single HRS run. The ELSD data were used to quantify the unknown active compounds, which, in combination with the bioassay data, allowed estimation of the potency (IC 50 ) of the inhibitors. Dereplication of the active sample was achieved using MS-MS and comparison with our self-compiled MS-MS library.
EXPERIMENTAL

Materials
Mant-cGMP and mant-adenosine 3′,5′-cyclic monophosphate (mant-cAMP) were purchased from Calbiochem (Darmstadt, Germany). Activator-deficient phosphodiesterase 3′,5′-cyclic nucleotide (PDE), calmodulin, HEPES, bovine serum albumin (BSA), polyethylene glycol MW 600 (PEG), 3-isobutyl-1-methylxanthine (IBMX), theophylline, and papaverine were obtained from Sigma-Aldrich (Steinheim, Germany). DMSO, methanol, and acetonitrile were purchased from Baker (Deventer, the Netherlands). ELISA blocking reagent (BR) was obtained from Boehringer Mannheim. Natural products extracts were kindly provided by Bayer (Wuppertal, Germany). The natural products extracts consisted of bacteria, fungi, and plant extracts, using either methanol or DMSO as the extraction solvent. After extraction, solvents were removed using freeze-drying followed by resuspending of the residue in DMSO. All other chemicals were purchased from Merck (Darmstadt, Germany) and were analytical grade.
Instrumentation
All experiments were carried out using a Gilson 235P autoinjector (Villiers-le-Bel, France) equipped with a Valco VICI 10port injection valve (Schenkon, Switzerland), an Agilent (Waldbronn, Germany) IsoPumps G1310A 1100 series, a MetaChem Technologies (Torrance, CA) MetaVac in-line 8-channel degasser and 2 Agilent fluorescence detectors 1100 series (excitation wavelength, 280 nm; emission wavelength, 460 nm), and an Agilent DAD detector 1100 series (wavelength, 254 nm). Two Shimadzu (Kyoto, Japan) CTO-10ACvp column ovens were used to control the reaction temperature and the temperature of the LC separation. Two Pharmacia (Uppsala, Sweden) 50-mL Superloops placed in a Spark (Emmen, the Netherlands) Mistral column oven at 5°C were used for reagent addition using 0.02% sodium azide in water as displacement solution. All tubing consisted of 0.13-mm i.d. PolyEtherEtherKetone (PEEK), except for the reaction coil, which was made of 0.25-mm i.d. × 0.4-mm o.d. PolyTetraFluoroEthylene (PTFE). In the HRS mode, a custommade LC-Packings (Amsterdam, the Netherlands) flow-splitter was used. All instrument control and data acquisition, except for the MS, were performed using ScreenControl, version 3.0 (Kiadis, the Netherlands). Data processing was done using ScreenAnalysis, version 3.0 (Kiadis, the Netherlands).
Mass spectrometry was performed on a Micromass quadrupole-orthogonal-acceleration time-of-flight mass spectrometer (Q-TOF micro MS) equipped with a LockSpray (electrospray) source (Micromass Ltd., Wythenshawe, Manchester, UK). Instrument control, data acquisition, and data processing were done using Masslynx software, version 4.0. The Q-TOF micro MS instrument was operated in "full-scan" MS with a spectrum integration time of 1 sec in the range of m/z 100-900 ("interscan" time 0.1 sec). Acquisition was performed in the continuum mode. The electrospray source conditions were as follows: capillary voltage, 3.0 kV; sample cone voltage, 25 V; extraction voltage, 2 V; source temperature, 150°C; desolvation temperature, 350°C; cone gas, 50 L/h; and desolvation gas, 600 L/h. ELSD was performed using a Sedere (Allfort Ville, France) SEDEX 75 detector.
Development of the continuous-flow PDE assay
A scheme of the continuous-flow PDE assay is shown in Figure  1 . The carrier solution consisted of 10 mM HEPES (pH 7.4), 90 mM KCl, 0.73 mM CaCl 2 , 5 mM MgCl 2 , and 0.02% sodium azide and was pumped at a flow rate of 100 µL/min. The PDE and mant-cGMP or PDE and mant-cAMP reagent solutions were kept at 5°C and were added to the carrier flow at 25 µL/min. PDE was dissolved in 10 mM HEPES buffer (pH 7.4) containing 90 mM KCl, 0.73 mM CaCl 2 , 5 mM MgCl 2 , 20 U/mL calmodulin, and 0.02% sodium azide. Mant-cGMP was dissolved in 10 mM HEPES buffer (pH 7.4) containing 90 mM KCl, 0.73 mM CaCl 2 , 5 mM MgCl 2 , and 0.02% sodium azide. The reaction coil had a volume of 150 µL. The influence of different parameters on the performance of the biochemical assay was studied and optimized, such as the PDE concentration, mant-cGMP, and the reaction temperature. In addition, the ability to reduce nonspecific binding of the assay reagents to the inner surface of the detection system was studied by dissolving different additives in the PDE solution. Finally, the influence of DMSO, methanol, and acetonitrile on the assay performance was studied by adding increasing concentrations of these organic modifiers to the assay carrier using 10 µM mant-cGMP, 4 mU/mL PDE, a reaction temperature of 30°C, and 0.05% BSA in the PDE solution.
FlowScreening of natural products extracts using the continuous-flow PDE assay
The natural products extracts in DMSO were diluted to a final concentration of 5% DMSO. To minimize matrix effects caused by the injected sample, DMSO was also added to the carrier solution to a final concentration of 5%. After centrifugation of the samples, FlowScreening was performed by injecting 5 µL of the diluted sample in 2 parallel assay lines. Both assay lines were configured as described in the previous paragraph with the exception that in 1 assay line, the enzyme was omitted. Because the response in the first assay line is a sum of the responses of the bioactivity and background fluorescence of the sample, the second line was used to enable background fluorescence correction. The continuous-flow PDE assay performance for hit identification was judged by calculating the Z′ and Z factor according to Zhang et al. 26 
LC coupled online to parallel PDE assay and chemical analysis
For the online coupling of the PDE assay to LC, a Phenomenex (Torrance, CA) 50 × 2.0-mm i.d. stainless-steel column packed with Luna C18 3-µm particles and a 4.0 × 2.0-mm i.d. guard column packed with C18 5-µm particles were used. Separation of the compounds in the plant extract (injection volume, 50 µL) was performed with a linear gradient elution from 5% to 95% methanol in 10 min and held constant at 95% for an additional 5 min. By using the Kiadis BioGradient technology 20 for elution, the flow rate entering both assay lines was held constant at 100 µL/min and contained a constant organic modifier percentage of 5%. A postcolumn splitter was inserted to obtain a continuous flow of 100 µL/min to both assay lines, 150 µL/min to the MS, and 650 µL/min to the DAD and to the ELSD. Then, 20 ng/µL erythromycin A dissolved in 0.1% acetic acid/methanol (50/50%, (v/v)) was continuously added at 4 µL/min using the LockSpray. After data acquisition, lock mass adjustment was performed using erythromycin A (m/z 734.4690 due to the protonated molecule) to allow accurate mass determination. Plant extracts in DMSO were centrifuged, and the supernatant was diluted with water to a final DMSO concentration of 5%. Spiking of the plant extract was performed by adding an appropriate amount of theophylline and papaverine to a plant extract to obtain a final inhibitor concentration of 250 µM.
RESULTS AND DISCUSSION
Development of the continuous-flow PDE assay
Proof of principle. The PDE enzymatic assay presented here is based on a difference in fluorescence intensity of 40% between substrate, mant-cGMP, and the conversion product of mant-cGMP, mant-GMP. A scheme of the continuous-flow PDE assay is shown in Figure 1 . In the enzymatic assay, PDE and mant-cGMP are simultaneously added to a carrier flow. In the reaction coil, fluorescent mant-cGMP is hydrolyzed by PDE to the less fluorescent mant-GMP. A constant enzymatic activity will result in a constant fluorescence intensity detected by the fluorescence detector. Inhibitors injected in the carrier flow will reduce the activity of PDE in the reaction coil. As a result, the enzyme will hydrolyze less mant-cGMP, and therefore a temporary increase of the fluorescence intensity will be observed. The basic principles of this continuousflow enzymatic assay format are demonstrated in Figure 2 . The addition of buffer to the carrier flow instead of PDE and mant-cGMP results in detection of a low-fluorescence intensity ( Fig. 2A) . A strong increase of the fluorescence is observed upon addition of mant-cGMP to the carrier flow, resulting in a constant fluorescence signal (Fig. 2B ). Subsequent addition of PDE results in a decrease of the fluorescence signal of about 15% (Fig. 2C) , indicating the hydrolysis of mant-cGMP to mant-GMP. The decrease in fluorescence is only 15% instead of the maximum 40% (indicated with the dotted line) as a consequence of the short reaction time of 1 min to convert mant-cGMP to mant-GMP. Injection of a concentration range of 100, 50, 25, 10, 5, and 1 µM IBMX resulted in concentrationdependent peaks (Fig. 2D) . The injection of a "blank" sample shows no peak at all. These results demonstrated that the hydrolysis of mant-cGMP by PDE in the reaction coil was inhibited by injection of an inhibitor. As can be observed in Figure 2 , 100 µM IBMX was capable of completely inhibiting all PDE activity, resulting in the maximum assay response. Similar experiments were performed using mant-cAMP as a substrate. However, much higher detection limits were obtained using this substrate. As a consequence, mant-cGMP was chosen for further experiments.
Optimization of continuous-flow PDE assay. The continuousflow PDE assay presented here was developed for the detection of PDE inhibitors at low concentration levels present in natural products extracts. Hence, the goal of the assay optimization is primarily focused on optimizing the assay sensitivity.
First, experiments were performed to optimize the PDE concentration using 20 µM mant-cGMP and a reaction temperature of 20°C. To study the influence of the PDE concentration on the assay performance, we injected increasing concentrations of IBMX at different PDE concentrations in the assay. The results of these experiments are presented in Figure 3A . This figure clearly demonstrates that an increase of the PDE concentration results in an increase of the assay response with a maximum at 4 mU/mL PDE, irrespective of the inhibitor concentration. Addition of higher concentrations than 4 mU/mL PDE results in a decrease of the assay response. Hence, further optimization of the assay was performed using 4 mU/mL PDE. The second assay parameter that was optimized was the mant-cGMP concentration at a reaction temperature of 20°C. Figure 3B shows the signal-to-noise ratios of injections of 100 µM IBMX at increasing mant-cGMP concentrations. The initial increase in assay sensitivity upon increasing the substrate concentration can be explained by an increased enzymatic turnover rate at higher substrate concentrations. 27 The decrease of the assay sensitivity upon addition of more than 10 µM mant-cGMP is caused by the increase of the noise as a result of an increased fluorescence background from mant-cGMP. The continuation of the assay optimization was performed using 10 µM mant- cGMP. The reaction temperature was the third assay parameter that was optimized. The influence of the reaction temperature on the assay sensitivity is presented in Figure 3C . Increasing the temperature results in an increase of the assay sensitivity with a maximum at 30°C due to increased reaction kinetics. Denaturation of the proteins is probably the cause of the decrease in assay sensitivity at temperatures higher than 30°C. In further optimization experiments, the reaction temperature was set at 30°C. The final assay optimization step consisted of the reduction of nonspecific binding of assay reagents to the inner surface of the continuous-flow detection system. Hereto, different reagents, commonly used to reduce nonspecific binding, 28 were added to the PDE solution. Subsequently, the assay performance was determined by injecting increasing concentrations of IBMX. The influence of the different additives on the inhibition curves of IBMX is presented in Figure   3D . All additives increased the background fluorescence and consequently increased the noise. Only the use of 1% BR and 0.05% BSA increased the assay sensitivity by around 50% and 85%, respectively, compared to using a PDE solution without additives. The increased signal-to-noise ratios were a consequence of a reduction of peak widths, resulting in a higher signal. The reduction of peak widths was most likely caused by the reduction of nonspecific binding. Higher concentration of BSA or BR did not result in better signal-to-noise ratios. However, addition of 0.05% PEG, 0.01% BSA, and 0.5% Tween-20 to the PDE solution decreased the assay sensitivity. In these cases, peak widths were not significantly reduced, and the peak height remained unchanged, which resulted in lower signal-to-noise ratios compared to using a PDE solution without additives. Finally, it was chosen to add BSA to the PDE solution with a final concentration of 0.05%. In conclusion, the optimized assay parameters were 4 mU/mL PDE containing 0.05% BSA, 10 µM mant-cGMP, and a reaction temperature of 30°C.
Screening for Phosphodiesterase Inhibitors
Application of the continuous-flow PDE assay to the screening of natural products extracts
FlowScreening. The FlowScreening mode is used to rapidly select active natural products extracts ("hits") from a natural products extracts library containing around 10,000 extracts. Prior to FlowScreening of the natural products extracts, the effect of DMSO on the assay readout was studied. The presence of 5% DMSO in the carrier solution reduced the assay response to about 60% of the response without DMSO, which was probably caused by the denaturing effect of DMSO on the proteins. However, most continuous-flow biochemical assays tolerate higher DMSO concentrations compared to batch assays used in HTS because of the short exposure time of the proteins to the DMSO.
First, the quality of the FlowScreening assay was determined by screening five 96-well plates containing negative controls (carrier solution) and positive controls (100 µM IBMX in carrier solution). A typical data set obtained after FlowScreening of negative and positive controls is presented in Figure 4A . A large difference between the positive and negative reference controls and a small data variability band resulted in a large separation band. To determine the influence of our natural products extracts library on the FlowScreening assay, we screened five 96-well plates containing natural products extracts (NPE) and natural products extracts containing 100 µM IBMX (spiked NPE). A typical data set obtained after FlowScreening of natural products extracts and spiked natural products extracts is presented in Figure 4B . As a consequence of screening the natural products extracts library, the dynamic range decreases and the data variability band increases, leading to a reduced separation band (cf. Fig. 4A,B) . The Z′ and Z factor of 0.85 and 0.6, respectively, indicate that the performance of the developed continuous-flow PDE assay is suitable for the use of hit identification. 26 After optimization of the continuous-flow PDE assay, the limit of detection was 1 µM IBMX (signal/noise = 3). The PDE assay had a dynamic range from 1 to 100 µM IBMX.
High-resolution screening. Prior to the online coupling of the assay with LC, the influence of organic modifiers commonly used in reversed-phase LC separation, such as methanol and acetonitrile, on the assay performance was studied. Increasing the methanol concentration in the assay to 10% caused a linear decrease in assay sensitivity to 65% of the response without the organic modifier. At a concentration of 10% acetonitrile in the assay, a decrease of assay sensitivity to 40% of the response without the organic modifier was observed. Because acetonitrile has a much stronger negative influence on the assay compared to methanol, the reversed-phase LC separation was performed using methanol as an LC eluent.
After primary screening of natural products extracts using the FlowScreening process, hits were reanalyzed using the HRS technology. To demonstrate the applicability of the HRS technology for dereplication, a plant extract was spiked with 2 naturally occurring PDE inhibitors (theophylline and papaverine) and analyzed by HRS-PDE assay. The sample was separated by gradient LC, and online the bioactivity, native fluorescence, DAD, MS, and ELSD were measured in parallel. After the LC column, a postcolumn flow-split was used to split 100 µL/min to the bioassay, 100 µL/ min to the native-fluorescence detection, 150 µL/min to the MS, and 650 µL/min to the DAD and ELSD. The reaction coil present in both the bioassay and the native-fluorescence line caused a time Figure 5 shows the data output from a single HRS run after time delay corrections. The bioassay chromatogram (Fig. 5A ) shows 3 peaks caused by active, nonactive-fluorescent, or active-fluorescent compounds eluting from the LC column. The native-fluorescence chromatogram ( Fig. 5B ) is used to correct for native fluorescence of the compounds. Subtracting the native-fluorescence chromatogram (after correction for the intrinsic sensitivity difference between both fluorescence detectors) from the bioassay chromatogram yields the peaks caused by bioactive compounds. Hence, peaks 1 and 3 could be identified as bioactive compounds. Peak 2 was caused by a native-fluorescent compound. Data analyses will only be focused on the bioactive compounds, peaks 1 and 3. All other peaks are irrelevant because they correspond to nonactive compounds.
To allow quantification of the unknown active compounds, ELSD detection was performed. The signal intensity of the ELSD detector mainly depends on the amount and not the physiochemical properties of the compound detected. Hence, after calibration, LC-ELSD can be used to quantify unknown compounds in a complex mixture. The quantification data can be used for 2 purposes. First, in combination with bioactivity data, a rough estimation of the IC 50 value of an active compound can be obtained, which is useful for hit ranking. Second, knowledge of the amount present in the plant extract is useful for judging the feasibility of compound isolation for follow-up studies. Using this approach, we determined that peaks 1 and 3 were caused by 2 µg and 4 µg of a bioactive compound, respectively (Fig. 5C ). The IC 50 values of bioactive compounds 1 and 3 were estimated to be 100 µM and 75 µM, respectively. For these calculations, molecular masses as measured with MS were used (see next paragraph). Unfortunately, to our best knowledge, no IC 50 values are reported for the same enzyme. Hence, no reliable comparison to a value reported in literature can be made.
For identification purposes, DAD and MS detection were performed. The DAD chromatogram (Fig. 5D ) shows that both bioactive compounds absorb UV light at 254 nm. This gives useful information about the presence of double bonds in the structure of the molecule, which can be helpful for identification. Peaks 1 and 3 in the total-ion current MS chromatogram (Fig.  5E ) correspond to both bioactive compounds. The "full-scan" MS spectrum (not shown) of active compound 1 shows 1 major peak at an m/z value of 181.073. This ion is considered to be the protonated molecule of the bioactive compound. To obtain more information on the identity of the bioactive compound, we analyzed the ion with an m/z of 181.073 with MS-MS. The MS-MS spectrum of this ion is presented in Figure 6A . This spectrum was subjected to a comparison with our self-compiled MS-MS library. A successful match was obtained with the MS-MS spectrum of theophylline from our spectral library (Fig. 6B) . The full-scan MS spectrum (not shown) of active compound 3 shows 1 major peak at an m/z value of 340.155. The MS-MS spectrum of this ion is presented in Figure  6C . After library comparison, active compound 3 was tentatively identified as papaverine (Fig. 6D) .
CONCLUSIONS
A continuous-flow PDE assay was developed for the purpose of finding and identifying PDE inhibitors in natural products extracts using the HRS technology. The HRS technology has proven to be an effective shortcut to identify PDE inhibitors in natural products extracts overcoming fraction collection and subsequent batch assays. As is frequently the case in identifying active compounds from natural sources, the original natural products extract also in- cludes some active analogs, which can easily be distinguished using HRS. Early identification of several structurally related active compounds could speed up the structure-activity relationship studies. The FlowScreening process, using a second assay line for background correction, is an efficient tool to increase the throughput of the primary screening and was very well suited for hit identifica-tion. Reanalysis of active extracts using the HRS approach eliminates the false positives and yields valuable information, such as UV absorbance, molecular mass, and MS-MS fragmentation pattern of the active compound within a very short time. The information provided by the HRS technology allows a very efficient and fast dereplication process. In addition, the hits can be ranked according to their activity, abundance, and/or structural information. 
